<DOC>
	<DOCNO>NCT02799823</DOCNO>
	<brief_summary>The purpose study evaluate safety performance HLT System patient severe aortic stenosis present High Risk aortic valve replacement surgery .</brief_summary>
	<brief_title>Transfemoral Replacement Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . 70 year age old 2 . Echocardiographic hemodynamic base evidence calcific ( senile ) aortic stenosis one following : aortic valve EOA &lt; 1.0 cm2 0.6 cm2/m2 , mean aortic valve gradient &gt; 40 mmHg peak aortic valve velocity &gt; 4 m/sec 3 . Symptomatology due aortic stenosis result one following : 1 . NYHA Functional Classification II great 2 . Presence angina 3 . Presence syncope 4 . Aortic valve annular diameter ≥ 24 ≤26 mm measure MSCT base area perimeter 5 . STS score ≥8 , document heart team agreement high risk surgical aortic valve replacement ( SAVR ) due frailty comorbidities . 6 . Geographically available , willing comply follow able provide write informed consent 1 . Congenital unicuspid bicuspid aortic valve , noncalcified aortic valve ; valve eccentricity ( calcific otherwise ) opinion investigator could compromise procedural success . 2 . Patients high risk coronary obstruction opinion investigator ( e.g . combination coronary height &lt; 12 mm coronary sinus diameter &lt; 30 mm ) 3 . Patients low flow/low gradient aortic stenosis 4 . Patients significant annular calcification ( e.g . Agatston score &gt; 4000 ) 5 . Preexisting prosthetic heart valve position , prosthetic ring 6 . Severe ( Grade 3 4 ) aortic , mitral tricuspid valve regurgitation 7 . Moderate severe mitral stenosis 8 . Myocardial infarction within past 30 days* 9 . Echocardiographic evidence intracardiac mass , thrombus vegetation 10 . LVEF &lt; 30 % 11 . Severe pulmonary hypertension pulmonary systolic pressure great twothirds systemic pressure 12 . Hemodynamic instability require inotropic drug therapy within past 14 day 13 . Untreated clinically significant coronary artery disease require revascularization 14 . Presence significant aortic disease atheroma , thrombus , aneurysm , opinion investigator , preclude safe implant delivery 15 . Blood dyscrasia define : acute leukopenia , acute anemia , acute thrombocytopenia , history bleed diathesis coagulopathy 16 . Patient ineligible refuse blood transfusion 17 . Unfavorable peripheral vascular anatomy disease ( e.g . severe obstructive calcification , severe tortuosity vessel &lt; 6 mm ) would preclude passage catheter femoral arterial access aorta evidence peripheral MSCT 18 . Active peptic ulcer gastrointestinal bleeding within past 90 days* 19 . Symptoms carotid vertebral artery disease ( e.g . stroke transient ischemic attack ) within past 6 month , treatment carotid stenosis within past two months* 20 . Renal insufficiency demonstrate serum creatinine &gt; 2.5 mg/dL end stage renal disease require chronic dialysis 21 . Active infection require ongoing treatment 22 . Need emergent surgery intervention investigational procedure 23 . Any therapeutic invasive cardiac procedure perform plan perform within 30 day index procedure* 24 . Hypersensitivity contraindication procedural medication device material ( e.g . titanium , nickel , pork ) adequately premedicated 25 . Life expectancy &lt; 1 year due noncardiac comorbid condition 26 . Currently participate investigational drug device study may confound result study 27 . History cognitive mental health status would interfere study participation 28 . Following surgical consultation , patient deem inoperable event surgical intervention require HLT valve implantation attempt .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>aortic stenosis</keyword>
	<keyword>transcatheter aortic valve replacement</keyword>
</DOC>